On September 29, WUXI XDC fell 3.34% in regular trading, trading at HK$77.0/share, with turnover of HK$198 million. The decline was driven by the lingering impact of a major shareholder stake reduction combined with broad-based weakness across the Life Sciences Tools & Services sector.

On the news front, WuXi AppTec sold 53.524 million shares of WUXI XDC via block trade at the end of August at an average price of HK$73.23 per share, totaling approximately HK$3.92 billion. This reduced WuXi AppTec's stake from 18.36% to 14.14%, and the overhang from this concentrated disposal continues to weigh on market sentiment nearly a month later.

Sector-wide, Life Sciences Tools & Services stocks traded under pressure. Among peers, GENSCRIPT BIO fell 4.14%, WUXI BIO declined 1.5%, while WUXI APPTEC edged up 0.39%. The sector-level drag amplified the stock's decline. Notably, Goldman Sachs recently issued a Buy rating on WUXI XDC with a target price of HK$97.9, citing upcoming FDA inspection of its Wuxi manufacturing facility as a key commercial milestone, and Schroders PLC raised its stake to 5.01% in mid-September.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)